The LuTectomy trial (NCT04430192) is an Australian open label, phase I/II non-randomized study evaluating neoadjuvant 177Lu-PSMA-617 (one or two cycles) followed by radical prostatectomy + pelvic lymph node dissection in patients with high risk localized or locoregional advanced prostate cancer and PSMA-avid disease. Here, FOLH1 is linked to prostate cancer.